Sie suchten nach: liposarcoma (Englisch - Schwedisch)

liposarcoma
liposarkom

liposarcoma nos
liposarkom

myxoid liposarcoma
myxoidliposarkom

liposarcoma, malignant
liposarkom

liposarcoma; embryonal
myxoidliposarkom

liposarcoma (diagnosis)
liposarkom

liposarcoma (morphologic abnormality)
liposarkom

translocated in liposarcoma protein
rna-binding protein fus

liposarcoma, no icd-o subtype
liposarkom

myxoid liposarcoma (morphologic abnormality)
myxoidliposarkom

liposarcoma, myxoid [disease/finding]
myxoidliposarkom

[m]liposarcoma nos (morphologic abnormality)
liposarkom

study 309 - overall survival in the liposarcoma subgroup
studie 309 – total överlevnad i liposarkomsubgruppen

liposarcoma, no icd-o subtype (morphologic abnormality)
liposarkom

liposarcoma, no international classification of diseases for oncology subtype
liposarkom

efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.
effektdata är huvudsakligen baserade på patienter med liposarkom och leiomyosarkom.

liposarcoma, no international classification of diseases for oncology subtype (morphologic abnormality)
liposarkom

the committee noted that evidence of yondelis’ s effects is mainly based on the treatment of liposarcoma and leiomyosarcoma.
kommittén noterade att bevisen på yondelis effekter huvudsakligen baseras på behandling av liposarkom och leiomyosarkom.

halaven was also studied in 143 patients with liposarcoma who had previously undergone at least two other treatments, which included an anthracycline.
halaven undersöktes också på 143 patienter med liposarkom som tidigare hade genomgått minst två andra behandlingar där det ingick en antracyklin.

additionally, halaven prolonged the length of time that liposarcoma patients lived, and this was considered important as these patients have limited treatment options.
halaven ökade dessutom den tid patienter med liposarkom levde och detta ansågs viktigt eftersom dessa patienter har begränsade behandlingsalternativ.